Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Regulation of Heart Rates

Regulation of Heart Rates

The regulation of heart rate is a complex process controlled by the autonomic nervous system (ANS), hormonal influences, and intrinsic cardiac mechanisms. The ANS has two main components: the sympathetic nervous system (SNS) and the parasympathetic nervous system (PNS).
The SNS increases heart rate through the release of norepinephrine and epinephrine, which act on beta-1 adrenergic receptors in the heart. This action increases the rate of depolarization in the sinoatrial (SA) node, the heart's...

Pathophysiology of Cardiac Performance

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...

Heart Failure II: Pathophysiology

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

Development of the Heart

Development of the Heart

The development of the human heart, a crucial organ, commences from the mesoderm on the 18th or 19th day after fertilization. This process initiates in the cardiogenic area, a group of mesodermal cells at the embryo's head end, which evolves into elongated strands known as cardiogenic cords. These cords undergo a transformation to form hollow-centered endocardial tubes.
As the embryo undergoes lateral folding, these paired tubes approach each other, merging into a single primitive heart...

Pathophysiology of Heart Failure

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Loss of lncRNA <i>H19</i> impairs neonatal cardiac regeneration.

American journal of physiology. Cell physiology·2026

Same author

RNA splicing and cardiovascular disease: a guide for cardiologists.

European heart journal·2026

Same author

Time- and spatially resolved LNA delivery via thermally controlled SPION technology.

Molecular therapy. Nucleic acids·2026

Same author

Telomere damage-mediated senescence in alveolar epithelial type II cells but not in macrophages aggravates inflammation in acute lung injury.

Respiratory research·2026

Same author

mRNA-based SARS-CoV-2 vaccines: intracellular processing and aggregation of the encoded spike protein as a mechanistic contributor to cardiac cellular stress.

Frontiers in immunology·2026

Same author

Macrophage-specific circular RNA circHIPK2, inflammation, and fibrosis after myocardial infarction.

European heart journal·2026

Same journal

Hyocholic acids: Third bile acids for neonatal health.

Trends in molecular medicine·2026

Same journal

Clonal hematopoiesis in Alzheimer's brain: Protective, pathogenic, and context-dependent?

Trends in molecular medicine·2026

Same journal

Targeting amino acid metabolism in hepatocellular carcinoma.

Trends in molecular medicine·2026

Same journal

Turning perfusion into repair through ferroptosis blockade.

Trends in molecular medicine·2026

Same journal

CaMKK2: A tumor stress-integration node.

Trends in molecular medicine·2026

Same journal

Precision gene editing: From proof-of-concept to curative therapies.

Trends in molecular medicine·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 1, 2026

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk

Published on: July 27, 2022

Linc-ing the Noncoding Genome to Heart Function: Beating Hypertrophy.

Shambhabi Chatterjee¹, Christian Bär¹, Thomas Thum¹

¹Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Germany.

Trends in Molecular Medicine

|June 4, 2017

Summary

This summary is machine-generated.

Aberrant gene expression is key in heart failure. Long non-coding RNAs (lncRNAs) are crucial regulators and potential therapeutic targets for improving cardiac hypertrophy treatments.

Keywords:

cardiac hypertrophy cardiovascular disease diagnostics long noncoding RNA ncRNA biomarker therapeutics

More Related Videos

Author Spotlight: Cardiac Cell Transgenesis for Rapid Gene Screening

Author Spotlight: Cardiac Cell Transgenesis for Rapid Gene Screening

Published on: May 24, 2024

High Efficiency Differentiation of Human Pluripotent Stem Cells to Cardiomyocytes and Characterization by Flow Cytometry

High Efficiency Differentiation of Human Pluripotent Stem Cells to Cardiomyocytes and Characterization by Flow Cytometry

Published on: September 23, 2014

Related Experiment Videos

Last Updated: Mar 1, 2026

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk

Published on: July 27, 2022

Author Spotlight: Cardiac Cell Transgenesis for Rapid Gene Screening

Author Spotlight: Cardiac Cell Transgenesis for Rapid Gene Screening

Published on: May 24, 2024

High Efficiency Differentiation of Human Pluripotent Stem Cells to Cardiomyocytes and Characterization by Flow Cytometry

High Efficiency Differentiation of Human Pluripotent Stem Cells to Cardiomyocytes and Characterization by Flow Cytometry

Published on: September 23, 2014

Area of Science:

Molecular biology
Genetics
Cardiology

Background:

Aberrant gene expression is a hallmark of various disorders, notably heart failure.
Long non-coding RNAs (lncRNAs) play significant roles in regulating genetic networks.
lncRNAs interact extensively with their genetic environment, making them promising therapeutic targets.

Purpose of the Study:

To explore the functional roles of lncRNAs in cardiac hypertrophy.
To identify potential therapeutic strategies for heart failure based on lncRNA function.

Main Methods:

Investigated the regulatory functions of lncRNAs in cardiac hypertrophy models.
Analyzed the interactions between lncRNAs and genetic networks in the heart.

Main Results:

lncRNAs are identified as key regulators in the development of cardiac hypertrophy.
Demonstrated the potential of targeting lncRNAs for therapeutic interventions in heart failure.

Conclusions:

Understanding lncRNA functions in cardiac hypertrophy can lead to novel therapeutic approaches.
lncRNAs represent a promising frontier for developing improved treatments for heart failure.